Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction

Repligen

Status and phase: Terminated; Phase 3

Conditions: Autism

Treatments: Drug: RG1068 (Synthetic Human Secretin)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00036231

RG1068-03

Details and patient eligibility

About

The purpose of the study is to determine the effect of multiple doses of secretin on autism.

Sex: All

Ages: 32 to 59 months old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

• Autism
• Gastrointestinal dysfunction

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Double Blind